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introduction: Immunocompromised patients carry a high risk for invasive fungal disease 
(IFD), which is associated with high mortality.
Materials and methods: This is a retrospective chart review of a 4-year experience of 
amphotericin B lipid complex (ABLC) utilization for the management of suspected IFD at 
the Hematology/Oncology and Bone Marrow Transplantation unit at Makassed General 
Hospital, Beirut, Lebanon between January 2011 and December 2014. We focused 
on treatment strategy, response rate, and adverse drug events associated with ABLC 
therapy. We also reviewed ABLC indications in international guidelines beyond its Food 
and Drug Administration approval.
results: A total of 89 patients received ABLC therapy for suspected fungal infection. 
Forty-eight percent were treated for a possible fungal infection, 19% for a problable fungal 
infection, 12% based on hospital guidelines, and 20% based on treating physician’s rec-
ommendations. The overall response rate was 71%. Nephrotoxicity occurred in 24% of 
patients and serum creatinine improved in 10% of these patients. Moderate hypokalemia 
was observed in 61% of the patients and severe hypokalemia in 10% but was corrected 
in both cases. Hepatotoxicity was observed in 12% of the patients throughout ABLC 
therapy. Infusion-related reactions were observed in 36% of the patients. There was a 
decrease in the incidence of these reactions upon using combination of premedication 
drugs.
conclusion: In this study, ABLC proved to be an effective and safe option in the man-
agement of suspected IFD in immunocompromised patients failing previous therapies.
Keywords: amphotericin B lipid complex, invasive fungal disease, hematopoietic stem cell transplantation, 
nephrotoxicity, infusion-related reactions, guidelines
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inTrODUcTiOn
Immunocompromised patients, including those on cytotoxic 
chemotherapy and immunosuppressive regimens, which result in 
severe and prolonged neutropenia in addition to hematopoietic 
stem cell transplantation (HSCT) recipients, carry a high risk for 
invasive fungal disease (IFD), which is associated with a high 
mortality rate (1, 2). Early diagnosis and aggressive therapeutic 
approaches to IFD represent important strategies to reduce com-
plications and mortality of these infections (1, 2).
Amphotericin B deoxycholate (conventional amphotericin 
B) is a polyene with a broad-spectrum activity. It is active against 
most yeasts, filamentous, and dimorphic fungi. For decades, it 
has been considered the gold standard therapy against most 
systemic fungal infections (3). However, the extensive clinical 
experience obtained with this drug has shown that it is associ-
ated with a high risk of treatment limiting toxicity, including 
infusion-related reactions (IRRs), such as fever and chills, and 
nephrotoxicity (3). Concerns about its toxicity have led to the 
development of lipid-based formulations with reduced toxicity, 
increased therapeutic utility, and significant advance in drug 
delivery (4).
Three lipid formulations of amphotericin B have been devel-
oped and approved for the treatment of systemic fungal infections, 
two of which amphotericin B lipid complex (ABLC; Abelcet®) 
and liposomal amphotericin B (L-AMB; AmBisome®) are cur-
rently in widespread use, in addition to amphotericin B colloidal 
dispersion (ABCD). The lipid composition of all three of these 
preparations differs considerably and contributes to substantially 
different pharmacokinetic parameters. ABCD has a similar or 
higher frequency of IRRs compared with conventional ampho-
tericin B deoxycholate. This high frequency of IRRs resulted in 
discontinuation of at least one clinical trial and subsequently 
ABCD has been removed from the commercial market (5).
Amphotericin B lipid complex contains a high ratio of 
amphotericin B to lipid, in ribbon-like aggregates distinct from 
liposomes (6). Many studies compared ABLC and L-AMB. 
There was a considerable heterogeneity among the studies, and 
the major conclusion was that they were comparable except for 
higher IRRs with ABLC compared to L-AMB (7). In this respect, 
Craddock et al. (8) showed a marked decrease in IRRs reaction 
with ABLC while using premedications along with slow infusion 
rate, and even recommended a therapeutic algorithm that helps 
decreasing the rate of IRRs with minimal steroid use (8).
The aim of our study is to retrospectively review a 4-year 
experience of ABLC (Abelcet; Cephalon Ltd., Herts, UK) utiliza-
tion for the management of suspected fungal infections in a single 
center in Lebanon. We looked for the strategy of initiating ABLC 
therapy with respect to clinical characteristics and risk factors for 
IFD, clinical response to ABLC therapy, all-cause mortality, along 
with adverse events associated with the use of ABLC.
Amphotericin B lipid complex was used in this study based 
on guidelines recommendations and on several comparative 
studies evaluating safety, efficacy, and cost-effectiveness of 
ABLC compared to other formulations of amphotericin B (1, 7, 
9). It has been proven that 5 mg/kg ABLC delivers the highest 
tissue concentration of amphotericin B in the liver, spleen, lung, 
and brain compared to other formulations except in the renal 
tissue (10–12).
We also reviewed ABLC indications in different international 
guidelines beyond its original Food and Drug Administration 
(FDA) approval (refer to Table 1). Its use in different studies has 
been evaluated previously, based on The Collaborative Exchange 
of Antifungal Research (CLEAR) database, where most of the lit-
erature is based on retrospective analysis of patients who received 
ABLC with a microbiological proof of IFD (1).
MaTerials anD MeThODs
This is a retrospective chart review conducted at Makassed 
General Hospital, a 200-bed university hospital located in Beirut, 
Lebanon with a 40-bed Hematology/Oncology and Bone Marrow 
Transplantation unit, between January 2011 and December 2014. 
It included 89 adult neutropenic cancer patients and HSCT 
recipients who received at least two doses of ABLC (5 mg/kg/day). 
The hospital’s Institutional Review Board approved this study, 
and an informed consent was waived without patient consent 
due to its observational nature. We recorded demographic data 
and baseline clinical characteristics; strategy of treatment; use of 
antifungals prior to ABLC therapy; tolerability and adverse drug 
events (ADEs) associated with ABLC, including IRRs, nephro-
toxicity, hypokalemia, and hepatotoxicity; and premedication 
combinations used in the prevention of IRRs. Then, we evaluated 
clinical response to therapy and mortality among these patients.
antifungal Prophylaxis
During the study period, antifungal prophylaxis was prescribed 
according to hospital protocol based on two guidelines: the Third 
European Conference on Infections in Leukemia (ECIL-3) 2009 
guidelines for antifungal management in leukemia and HSCT 
recipients (22) and the 2011 National Comprehensive Cancer 
Network (NCCN) clinical practice guidelines in prevention and 
treatment of cancer-related infections (23). Risk stratification to 
fungal infections is based on several factors, including underly-
ing malignancy, whether disease is in remission, duration of 
neutropenia, prior exposure to chemotherapy, and intensity of 
immunosuppressive therapy. High-risk patients including those 
with leukemia undergoing induction/salvage chemotherapy and 
allogeneic HSCT recipients received prophylactic voriconazole 
(IV 6 mg/kg every 12 h × 2 doses, then 4 mg/kg every 12 h; oral 
200 mg PO BID). Recently, in 2014, posaconzaole (200 mg PO 
TID) was prescribed for this category of patients as per updated 
hospital protocol. Intermediate-risk patients including autolo-
gous HSCT recipients with mucositis only received prophylactic 
fluconazole or micafungin. Patients with chronic lymphocytic 
leukemia were prescribed fluconazole (400 mg IV/PO daily) in 
cases of prolonged neutropenia for >7 days or old age. Patients 
with lymphoma or multiple myeloma were not put on an anti-
fungal prophylaxis regimen except fluconazole (400 mg IV/PO 
daily) when there was evidence of oral and/or esophageal candida 
infections. Low-risk patients including those who receive stand-
ard chemotherapy regimens for most solid tumors and patients 
with anticipated neutropenia for <7  days were not given any 
prophylactic antifungals.
TaBle 1 | summary of recommendations for the use of amphotericin B lipid complex (aBlc) or other lipid formulations in the management of invasive 
fungal disease according to regional and international guidelines.
guidelines indication strength of 
recommendation-
quality of evidence
reference
Clinical Practice Guidelines for the Management 
of Candidiasis: 2009 Update by the IDSA
Candidemia in non-neutropenic patients A-Ia (13)
Candidemia in neutropenic patients A-IIa (C. albicans) B-IIIa (C. 
glabrata, C. parapsilosis, 
C. krusei)
Empirical treatment for suspected invasive candidiasis in non-neutropenic 
patients
B-IIIa
Empirical treatment for suspected invasive candidiasis in neutropenic 
patients
A-Ia
Treatment for neonatal candidiasis B-IIa
ESCMID guideline for the diagnosis and 
management of Candida diseases 2012: 
adults with hematological malignancies and 
after HSCT
Empiric therapy to treat possible Candida disease B-Ib (14)
Targeted treatment of invasive candidiasis/candidaemia C-IIb
Clinical practice guidelines for the management 
of invasive Candida infections in adults 
in the Middle East region: expert panel 
recommendations
Proven Candida infection non-neutropenic patients Aa (alternative) (15)
Proven Candida infection neutropenic patients Ba (alternative)
Suspected Candida infection non-neutropenic patients Ba (alternative)
Suspected Candida infection neutropenic patients Aa (primary)
Treatment of aspergillosis: Clinical Practice 
Guidelines of the IDSA
Invasive pulmonary aspergillosis A-Ia (primary) (16)
A-IIa (alternative)
Invasive sinus aspergillosis (if the etiological organism is not known or 
histopathologic examination is still pending in anticipation of possible 
sinus zygomycosis)
A-IIIa
Tracheobronchial aspergillosis B-IIIa (alternative)
Aspergillosis of the CNS B-IIIa (alternative)
Aspergillus osteomyelitis and septic arthritis B-IIa (alternative)
Aspergillus infections of the eye (endophthalmitis and keratitis) B-IIIa (primary)
Cutaneous aspergillosis A-Ia (alternative)
Aspergillus peritonitis B-IIIa (primary)
Renal aspergillosis C-IIIa
Empirical antifungal therapy of neutropenic patients with prolonged 
fever despite antibacterial therapy and presumptive therapy for invasive 
aspergillosis
A-Ia
Salvage therapy of invasive aspergillosis B-IIIb
Clinical practice guidelines for the treatment 
of invasive Aspergillus infections in adults 
in the Middle East region: expert panel 
recommendations
Invasive pulmonary aspergillosis Ba (alternative) (17)
Tracheobronchial aspergillosis Ca (alternative)
CNPA (subacute invasive pulmonary aspergillosis) Ca (alternative)
Aspergillosis of the CNS Cb (alternative)
Aspergillus infections of the heart (endocarditis, pericarditis, and 
myocarditis)
Ca (primary)
Aspergillus osteomyelitis and septic arthritis Ba (alternative)
Aspergillus infections of the eye (endophthalmitis and keratitis) Ba (alternative)
Cutaneous aspergillosis Ba (alternative)
Aspergillus peritonitis Ca (alternative)
ESCMID and ECMM joint guidelines 
on diagnosis and management of 
hyalohyphomycosis: Fusarium spp., 
Scedosporium spp., and others
Treatment of Fusarium infection C-IIIb (limited case reports) (18)
ESCMID and ECMM joint clinical guidelines 
for the diagnosis and management of 
mucormycosis 2013
First-line treatment of mucormycosis in adult patients except CNS
Salvage treatment of mucormycosis in adult patients: refractory to prior 
antifungal therapy, intolerant to prior antifungal, intolerant due to pre-
existing renal disease
B-IIb
B-IIb
(19)
(Continued)
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Diagnosis and Management
Diagnostic Workup
In patients with persistent fever at 72–96 h in the absence of focus 
of infection with relevant signs and symptoms, a chest X-ray is 
done and two sets of blood culture are withdrawn, one from 
central vascular access, and another from peripheral access. If no 
central vascular access is present, one set of blood culture is taken 
from peripheral access. A chest computed tomography scan is 
guidelines indication strength of 
recommendation-
quality of evidence
reference
ESCMID and ECMM joint clinical guidelines for 
the diagnosis and management of rare invasive 
yeast infections
Cryptococcus other than C. neoformans and C. gattii B-IIIa (20)
CNS and severe infection (induction)
Non-CNS, not severe infection
Geotrichum candidum B-IIIa
Kodamaea ohmeri B-IIIa
Malassezia (severe) B-IIIa
Pseudozyma spp. A-IIa
Rhodotorula A-IIa
Saccharomyces B-IIIa
Saprochaete capitata B-IIIa
Sporobolomyces C-IIIa
Trichosporon D-IIIa
European guidelines for antifungal management 
in leukemia and hematopoietic stem cell 
transplant recipients: summary of the ECIL 
5 – 2013 Update
Invasive candidiasis before species identification B-IIb Reference 
in 
footnotesc
Invasive Candidiasis (C. albicans, C. glabrata, C. parapsilosis, C. krusei) B-IIb
Invasive aspergillosis (first line) B-IIb
Invasive aspergillosis (Salvage) B-IIb
Mucormycosis first line (except CNS and renal failure) B-IIb
Mucormycosis (Salvage) B-IIIa
Clinical Practice Guideline for the Use of 
Antimicrobial Agents in Neutropenic Patients 
with Cancer: 2010 Update by the IDSA
Invasive aspergillosis A-III (mold-active agent) (21)
Anticipated prolonged neutropenic periods of at least 2 weeks C-III (mold-active agent)
Prolonged period of neutropenia immediately prior to HSCT (C-III) C-III (mold-active agent)
KEY: CNS, central nervous system; ECIL, European Conference on Infections in Leukemia; ECMM, European Confederation of Medical Mycology; ESCMID, European Society for 
Clinical Microbiology and Infectious Diseases; HSCT, hematopoietic stem cell transplantation; IDSA, Infectious Diseases Society of America.
N.B. Please refer to each corresponding guidelines for the grading system.
aLipid formulation of amphotericin B.
bAmphotericin B lipid complex.
chttp://www.kobe.fr/ecil/telechargements2013/ECIL5%20Antifungal%20Therapy.pdf
TaBle 1 | continued
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done if there is a new onset of cough or any new findings on lung 
exam. Sinuses CT scan is also done in case of any suggestive sign 
or symptom. In our institution, routine CT scans of chest and 
sinuses are not always done in persistently febrile neutropenic 
patients, in order to avoid moving these patients outside from 
the oncology ward, where the risk of exposure to dust might be 
higher. Bronchoalveolar lavage (BAL) is done in case of positive 
finding on chest CT scan and BAL fluid is sent for bacterial and 
fungal culture; however, the yield of fungal cultures in our institu-
tion is low due to technical difficulties. Serum galactomannan 
levels are recommended in the hospital protocol to be taken twice 
per week in persistently febrile neutropenic patients; however, it 
has not been consistently available in the hospital and the country 
during the study period. So, it was done as per hospital protocol 
when available.
Management
In our study, ABLC utilization was based on three things: The 
European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the National 
Institute of Allergy and Infectious Diseases Mycoses Study Group 
(EORTC/MSG) classification of IFD (24), hospital-based protocol 
for those who do not fit the EORTC/MSG criteria, and treating 
physician recommendations based on the patient’s condition.
With respect to EORTC/MSG categories, we had two levels of 
probability to diagnose IFD, which were “probable” and “possible” 
IFD. Probable IFD requires the presence of a host factor, a clinical 
criterion, and a mycological criterion. These cases are treated 
pre-emptively. Others that meet the criteria for a host factor and 
a clinical criterion but for which mycological criteria are absent 
are considered possible IFD and are thus treated empirically (24). 
Host factors include the following: recent history of prolonged 
neutropenia, receipt of an allogeneic HSCT, prolonged use of cor-
ticosteroids, and treatment with T cell immunosuppressants (24). 
Clinical criteria must be consistent with the mycological findings, 
if any, and must be related to current episode and confirmed by 
radiological investigations (24). Mycological criteria include direct 
testing through identification of fungal elements suggesting molds 
or recovery by culturing samples from sputum, bronchoalveolar 
lavage fluid, bronchial, or sinus aspirate; in addition to indirect 
tests such as serum galactomannan in cases of aspergillosis (24).
According to the hospital protocol, febrile yet clinically stable 
patients, at 72–96 h after the onset of fever having no focus of 
infection and negative serum galactomannan, were treated 
with caspofungin. ABLC was initiated in case of persistent 
neutropenic fever for ≥4  days in a patient receiving appropri-
ate antibiotic therapy in cases of (1) infiltrates or nodules on 
chest CT scans/X-Ray or suspected sinusitis based on sinus CT 
scan  ±  positive serum galactomannan in patients who were 
previously on mold-active azole prophylaxis (voriconazole), (2) 
clinical instability in high-risk patients with previous mold-active 
prophylaxis (voriconazole), and (3) autologous HSCT recipients 
with mucositis who are already on micafungin prophylaxis with 
negative serum galactomannan.
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response
Clinical success was defined as resolution of all pretreatment 
signs and symptoms of suspected fungal infection by the end of 
therapy confirmed by radiological and serological investigations 
(4, 25). Clinical failure was defined as the progression of disease 
or the lack of significant improvement or worsening of the same 
parameters including death the of the patient or drug withdrawal 
with evidence of ongoing infection after 7  days of antifungal 
therapy or onset of toxicity that would require discontinuation 
of the drug (4, 25).
adverse events
Nephrotoxicity was defined as a twofold increase in serum 
creatinine anytime above baseline during ABLC therapy (25). 
Improvement in renal function was defined as a decrease in serum 
creatinine level from a baseline value of ≥1.5 mg/dL to within the 
normal range or else a >20% decrease from the baseline value 
(4). Hepatotoxicity was defined as a threefold increase in hepatic 
transaminases anytime above baseline during ABLC therapy (25). 
Hypokalemia was defined as decrease in K+ level to <3.5 mEq/L. 
Moderate hypokalemia was having K+ level (>2.5–3.5  mEq/L) 
and severe hypokalemia <2.5 mEq/L (25). Reversible/correctable 
hypokalemia was defined as K+ level increasing to >3.5 mEq/L 
during ABLC treatment (25) through intravenous and/or oral 
potassium salt supplementation as per hospital protocol.
statistical analysis
Data were analyzed using SPSS version 19 (SPSS, Chicago, IL, 
USA). Descriptive statistics and frequencies were performed 
to obtain percentages. Chi square test was used to assess any 
significant difference the groups. P-value <0.05 was considered 
significant.
resUlTs
Patients’ characteristics, Treatment 
strategy, and Outcome
This study included 89 adult neutropenic cancer patients who 
received an ABLC dose of 5  mg/kg/day. The mean patient age 
was 43 years and 56% of the patients were males. In our series, 
no cases of proven fungal infections were diagnosed. Forty-three 
patients (48%) fulfilled the EORTC-MSG criteria of possible 
fungal infection and were treated empirically. Seventeen patients 
(19%) were treated preemtively for probable fungal infection. 
Twenty-nine patients (33%) did not fall under any category of 
the EORTC-MSG classification; yet, they were prescribed ABLC 
according to hospital guidelines or by their treating hematologist/
oncologist because of their either critical condition or persistence 
of fever in spite of empirical antibiotic therapy in addition to 
echinocandin or voriconazole prophylaxis. Fifty-seven patients 
(64%) showed evidence of documented infections like colitis and 
19 patients (21%) showed evidence of cytomegalovirus infection 
identified through viral polymerase chain reaction. In these 
patients, ABLC was not discontinued because of the assumption 
of the presence of more than one infection in such a severely 
ill category of patients. Thus, they were not excluded from the 
outcome analysis. No routine CMV-PCR is done to all patients 
except to those who develop colitis or have persistent fever in 
spite of appropriate antimicrobial treatment. The overall success 
rate was 71% and total mortality reached 29%. The calculated 
mortality is crude all-cause mortality not restricted to fungal 
infection as etiology (refer to Table 2).
adverse events
Nephrotoxicity
Nephrotoxicity occurred in 21/89 patients (23.6%). Out of these 
patients 18/89 (20.2%), had initially a baseline serum creatinine 
below 1 mg/dL and 3/89 (3.4%) had a baseline serum creatinine 
above 1  mg/dL. Serum creatinine improved in 3/89 (3.4%) of 
the whole population and remained persistently elevated in 
18/89 (20.2%) of the patients. All of our patients had conditions 
predisposing to renal impairment, including intake of nephro-
toxic anti-infectives and cytotoxic chemotherapeutic agents. 
Nephrotoxicity was managed by increasing hydration, stopping 
other concomitantly administered nephrotoxic medication, 
mostly aminoglycosides whenever possible. In our series, ABLC 
was not stopped in any of the cases due to persistently elevated 
serum creatinine according to benefit-risk ratio (refer to Table 3 
and Figure 1).
Hypokalemia
Hypokalemia occurred in 64/89 patients (72%) of which 60.7% 
(54/89 patients) was moderate hypokalemia and 10.1% (10/89 
patients) was severe. Hypokalemia was reversible in 56/89 
patients (62.9%) through intravenous and oral potassium salts 
supplementation as per hospital guidelines. Eight out of 89 
patients (9%) failed to get serum potassium levels back to normal 
and three of them had ABLC discontinued (refer to Table 4 and 
Figure 1).
Hepatotoxicity
Eleven (12.4%) patients out of 89 showed a threefold increase 
in hepatic transaminases (AST, aspartate aminotransferase and 
ALT, alanine aminotransferase) levels above baseline throughout 
ABLC therapy (refer to Figure 1).
Infusion-Related Reactions
All patients were premedicated prior to ABLC therapy, yet infu-
sion reactions including fever, chills, and rigors were observed in 
32/89 (36%). Several combinations of premedication drugs were 
used including intravenous rapid acting corticosteroids; steroids 
and paracetamol; steroids, paracetamol, and antihistamines. 
Among the patients premedicated with steroids alone, 3/23 
(13%) patients developed IRRs. Whereas patients premedicated 
with steroids and paracetamol, 18/44 (41%) of them developed 
IRRs. In patients premedicated with steroids, paracetamol and 
antihistamines, 9/16 (56.3%) developed IRRs (refer to Table  5 
and Figure 1).
Others
Considering other ADEs in our patient population, 6/89 (6.7%) 
experienced nausea and vomiting, 6/89 (6.7%) abdominal pain, 
TaBle 3 | nephrotoxicity due to amphotericin B lipid complex (aBlc).
Baseline serum 
creatinine <1 mg/dl
Baseline serum 
creatinine >1 mg/dl
% of each 
categorya
% of total 
(n = 89)b
% of each 
categorya
% of total 
(n = 89)b
Total 80/80 (100%) 80/89 
(88.6%)
10/10 (100%) 10/89 
(11.2%)
Doubling serum 
creatinine at 
anytime of ABLC 
therapy
18/80 (22.5%) 18/89 
(20.2%)
3/10 (30%) 3/89 (3.4%)
Serum creatinine 
back to baseline at 
anytime of ABLC 
therapy
3/18 (16.7%) 3/89 (3.4%) 0 0
Persistent elevation 
of serum creatinine
15/18 (83.3%) 15/89 
(16.9%)
3/3 (100%) 3/89 (3.4%)
Improving serum 
creatinine at the 
end of therapyc
1/18 (5.6%) 1/89 (1.1%) 0 0
N.B. Percentages were calculated in two ways.
aThe denominator was the total number of patients in each subgroup.
bThe denominator was the total number of patients in the study.
cImprovement in renal function was defined as a decrease in serum creatinine level 
from a baseline value of ≥1.5 mg/dL to within the normal range or else a >20% 
decrease from the baseline value.
TaBle 2 | clinical characteristics, diagnosis, treatment strategy, and 
outcome of patients receiving amphotericin B lipid complex therapy.
Patients’ characteristics number of patients 
(n = 89%)
age (years)
<20 3 (3.4%)
(20–40) 33 (37.1%)
(40–60) 43 (48.3%)
>60 9 (10.1%)
gender
Male 50 (56.2%)
Female 39 (43.8%)
Tumor type
Leukemia and myelodysplastic disorders on 
chemotherapy
37 (41.6%)
Lymphoma and other malignancies on 
chemotherapy
16 (18%)
Autologous HSCT 20 (22.5%)
Allogeneic HSCT 16 (18%)
Graft versus host disease 6 (6.7%)
Central venous catheterization 63 (70.8%)
Mechanical ventilation 19 (21%)
Colitis 57 (64%)
Cytomegalovirus infection 19 (21.3%)
Diagnosis and management
Based on EORTC-MSG classification of IFDa
Possible fungal infection treated empirically 43 (48.3%)
Probable fungal infection treated pre-emptively 17 (19.1%)
Outside the EORTC-MSG classification of IFD
ABLC therapy based on hospital protocolb 11 (12.4%)
ABLC therapy based on treating physician’s 
recommendationsc
18 (20.2%)
antifungal use prior to aBlcd
None 33 (37.1%)
Fluconazole 31 (34.8%)
Voriconazole 10 (11.2%)
Posaconazole 3 (3.4%)
Echinocandin 22 (24.7%)
response
Success 63 (70.8%)
Failure 26 (29.2%)
Mortality
Total mortality 26 (29.2%)
30-day post-treatment mortality 11 (12.4%)
KEY: ABLC, amphotericin B lipid complex; EORTC-MSG, European Organization for 
Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and 
the National Institute of Allergy and Infectious Diseases Mycoses Study Group; HSCT, 
hematopoietic stem cell transplantation; IFD, invasive fungal disease.
N.B. aEORTC-MSG classification of IFD is based on the three elements: host factors, 
clinical manifestations, and mycological evidence.
bABLC is initiated in case of persistent neutropenic fever for ≥4 days despite of 
antibiotic therapy in case of (1) infiltrates or nodules on chest computed tomography 
(CT) scans/X-Ray or suspected sinusitis based on sinus CT scan ± positive serum 
galactomannan in patients who were previously on mold-active azole prophylaxis, (2) 
clinical instability in high-risk patients with previous mold-active prophylaxis, and (3) 
autologous HSCT recipients with mucositis who are already on micafungin prophylaxis 
with negative serum galactomannan.
cTreating physician recommendations to avoid potential infectious complications in 
such a sick category of patients.
dMore than one agent may be used at different times.
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1/89 (1.1%) dyspnea, and 1/89 (1.1%) developed skin rash (refer 
to Figure 1).
DiscUssiOn
This is a retrospective chart review evaluating the use of ABLC in 
a single center in Lebanon. ABLC was used in this study based on 
guideline recommendations and on several comparative studies 
evaluating safety, efficacy, and cost-effectiveness of ABLC com-
pared to other formulations of amphotericin B (1, 7, 9). The Food 
and Drug Association (FDA) approved ABLC in 1995 for the treat-
ment of invasive fungal infections in patients who are refractory 
to or intolerant of conventional amphotericin B therapy (26). It 
appears, with mostly (B-II), (C-II), and sometimes (A-I) or (A-II) 
levels of recommendation and quality of evidence, in regional and 
international clinical practice guidelines for the management of 
invasive aspergillosis (16, 17, 27), invasive candidiasis in neutro-
penic and non-neutropenic patients (13–15), febrile neutropenia 
in cancer and HSCT patients (21, 22), and in the guidelines for 
the diagnosis and management of non-Aspergillus molds (18, 19). 
These indications are beyond the FDA approval. Refer to Table 1 
for further information about ABLC indications in regional and 
international guidelines.
In our study, which included 89 adult patients with neutro-
penic fever, the overall response rate was 71%. This result was 
better compared to a subset of patients with presumed fungal 
infection treated with ABLC in a retrospective study by Mehta 
et  al. (28) where the response rate reached 63%. Our study 
population is comparable to this subset of patients in this study, 
which included 64 adult neutropenic cancer patients who were 
TaBle 5 | infusion-related reactions (irr) associated with amphotericin B lipid complex using different premedication regimens.
Premedication protocol
hydrocortisone (h) only h + Paracetamol (P) h + antihistamine (a) P + a h + a + P
Number of premedicated patients 23 44 2 2 16
IRR 3 18 1 1 9
% 13 41 50 50 56.3
N.B. 2/89 patients were not premedicated and no infusion-related reaction occurred.
Premedication protocols.
IV Hydrocortisone (100–250 mg) alone.
IV Hydrocortisone (100–250 mg) + IV Paracetamol (1 g).
IV Hydrocortisone (100–250 mg) + Antihistamine: PO Hydroxyzine HCl (10 mg) or PO Loratidine (10 mg).
IV Paracetamol (1 g) + Antihistamine: PO Hydroxyzine HCl (10 mg) or PO Loratidine (10 mg).
IV Hydrocortisone (100–250 mg) + IV Paracetamol (1 g) + Antihistamine: PO Hydroxyzine HCl (10 mg) or PO Loratidine (10 mg).
TaBle 4 | hypokalemia due to amphotericin B lipid complex (aBlc).
serum potassium no hypokalemia (>3.5 meq/l) Moderate hypokalemia (>2.5–3.5 meq/l) severe hypokalemia (<2.5 meq/l)
% of each  
categorya
% of total  
(n = 89)b
% of each  
categorya
% of total  
(n = 89)b
% of each  
categorya
% of total  
(n = 89)b
Total 25/25 (100%) 25/89 (28.1%) 54/54 (100%) 54/89 (60.7%) 10/10 (100%) 10/89 (10.1%)
Reversible/correctable 0 0 47/54 (87%) 47/89 (52.8%) 9/10 (90%) 9/89 (10.1%)
Irreversible/not correctable 0 0 7/54 (13%) 7/89 (7.9%) 1/10 (10%) 1/89 (1.1%)
Discontinuation of ABLC 
due to hypokalemia
0 0 2/54 (3.7%) 2/89 (2.2%) 1/10 (10%) 1/89 (1.1%)
N.B. Percentages were calculated in two ways.
aThe denominator was the total number of patients in each subgroup.
bThe denominator was the total number of patients in the study.
FigUre 1 | adverse drug events (aDes) associated with the use of amphotericin B lipid complex (aBlc).
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immunocompromised after HSCT or chemotherapy. They 
received ABLC (5 mg/kg/day), with a total of 68 courses of ABLC 
therapy (16/68 courses for confirmed cases and 52/68 courses 
for presumed fungal infections) (28). In another key clinical trial 
on 556 patients conducted by Walsh et al. (4), the response rate 
was much less than ours (57%). The main difference between 
our patient population and Walsh et  al. (4) population is that 
ABLC was used in our study to treat fungal infections in immu-
nocompromised patients in indications outside FDA approval 
but mentioned in several regional and international guidelines, 
whereas Walsh et al. (4) used it strictly in patients intolerant or 
refractory to conventional amphotericin B, as per FDA approval.
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The safety and tolerability profile represent a major issue that 
affects the choice of antifungal therapy. In our study, nephrotox-
icity occurred in 24% of the patients; yet, ABLC was not discon-
tinued in any of the cases according to benefit–risk ratio knowing 
that all of our patients were on multiple nephrotoxic drugs. 
Nephrotoxicity is the most clinically significant adverse reaction 
of amphotericin B and the concomitant use of nephrotoxic agents 
(such as aminoglycosides, cyclosporine) or corticosteroids, 
cytotoxic chemotherapy is a well-known risk factor for ampho-
tericin B-induced nephrotoxicity (7). In a pharmacovigilance 
study conducted in Spain involving 93 oncology/hematology 
patients, no differences in major renal, hematological, and liver 
function parameters (serum creatinine, hemoglobin, potassium, 
transaminases, and bilirubin) were reported with ABLC when 
comparing pretreatment and post-treatment values (29). In a 
study by Alexander and Wingard on renal safety in ABLC-treated 
patients, nephrotoxicity was observed in 13% of subjects despite 
the high risk of renal impairment carried by these patients (30). 
Two meta-analyses of clinical efficacy and tolerability data, 
which compared lipid-based formulations of amphotericin B 
with conventional amphotericin B, concluded that the former are 
associated with less nephrotoxicity and hypokalemia compared 
to conventional amphotericin B (31, 32). However, partially 
due to controversial results and the heterogeinity of the studies, 
these meta-analyses failed to show any significant difference 
in renal safety between the different lipid-based formulations 
of amphotericin B (31, 32). In a literature review of published 
data on the safety, efficacy, and cost-effectiveness of ABLC, the 
author concluded that ABLC has a superior tolerability profile 
compared to conventional amphotericin B, and he also declared 
that ABLC and L-AmB have a similar risk of nephrotoxicity (9). 
In a recent review and meta-analysis that compared the drug-
induced nephrotoxicity associated with either ABLC or L-Amb, 
the authors reported an increased probability of nephrotoxicity in 
patients who were treated with ABLC as compared with L-AmB 
[odd’s ratio (OR), 1.75; relative risk (RR) 1.55] (33). This was 
due to the significant lack of homogeneity across these studies, 
where the results were heavily influenced by an unexplained high 
rate of nephrotoxicity in one particular study by Wingard et al. 
(34). When that study was removed from the analysis, the risk of 
nephrotoxicity was more similar between the two preparations 
(OR, 1.12; RR, 1.09) (33).
Hypokalemia secondary to urinary potassium wasting is a 
frequent adverse effect of amphotericin B therapy, where serum 
potassium levels should be routinely monitored (7). In our study, 
moderate hypokalemia was observed in around 61% of the cases 
and severe hypokalemia in 10%. Serum potassium levels were 
correctable in 63% of patients in both groups by supplying intra-
venous and oral potassium salts as per hospital guidelines. ABLC 
was discontinued due to hypokalemia in three patients only. 
According to a study by Clark et al. (35), electrolyte abnormalities 
were present in 18/36 (50%) patients on ABLC who experienced 
a fall in serum potassium levels on therapy to <3 mmol/L. Serum 
potassium should be routinely monitored with amphotericin B 
formulations since it has been clearly documented that it induces 
renal potassium wasting and can produce substantial potassium 
deficit (35).
Infusion-related reactions, such as fever and chills, which occur 
with ABLC, are generally mild to moderate and usually last for 
only 2–3 days after the onset of therapy. IRRs are not dose related 
and generally diminish with subsequent infusions (36). In our 
study, the overall rate of IRRs was 36% despite of premedication 
along with a slow infusion rate that was not standardized during 
the whole study period. Several combinations of premedication 
drugs were used including intravenous rapid acting corticoster-
oids alone; steroids and paracetamol; steroids, paracetamol, and 
antihistamines all together. Recent studies have highlighted the 
importance of premedication regimens combined with a reduc-
tion in the infusion rate to minimize, or even prevent, the onset 
of IRRs, which are based on the administration of systemic cor-
ticosteroids, paracetamol, with or without chlorphenamine (8). 
The reported incidence of IRRs with ABLC has ranged between 
2 and 23% in several studies (28, 29). It has been postulated that 
slowing the speed of the ABLC infusion, i.e., to run the dose over 
3–4  h has been proven in the literature to decrease the rate of 
IRRs (8). IRRs are common to all lipid-based formulations of 
amphotericin B, although L-AMB has been shown to result in 
a lower incidence than ABLC (37). Yet, they can be easily man-
aged through a combination of premedication and reducing the 
infusion rate of ABLC. In a study by O’Connor and Borley (38), 
100 mg of hydrocortisone was used as premedication 15–30 min 
prior to ABLC infusion. This resulted in a lower incidence of 
IRRs than had been reported in published literature for ABLC, 
15.3% for the initial infusion and 2.3% for subsequent infusions 
(38). Craddok et al. (8) suggested a consensus panel algorithm 
on premedication and infusion rate to reduce the risk of IRRs 
following ABLC infusion.
There are few reports in the literature of ABLC-induced 
hepatotoxicity (39). In our study, we observed that 12.4% patients 
out of 89 showed a threefold increase in hepatic transaminases 
levels above baseline throughout ABLC therapy. However, it is 
rare as shown by Hashem et al. (25) where it was observed in 4/52 
patients (7.7%) who received ABLC as primary therapy for the 
treatment of invasive aspergillosis.
This study has a major limitation that it is only descriptive and 
retrospective. No comparison was made to other antifungals or a 
control group in addition to the heterogeneity of our patient pop-
ulation including different categories of risk to fungal infections. 
Although the immunological response in this heterogeneous 
group of patients differs from one clinical condition to another, 
it is still comparable to earlier studies that evaluated the efficacy 
and tolerability of polyene antifungals (4, 28). Fungal attributable 
mortality was not discussed because of the complexity of the cases 
even if it maybe partially attributed to fungal infection. Yet, the 
basic illness, severity of immunosuppression, and thrombocyto-
penia would have played a major role in the etiology of mortality 
and can be major confounding factors, add to this that autopsies 
were not done in this specific population, where family consent 
can rarely be obtained. In addition, an ideal study would include 
microbiological confirmation of fungal infection before starting 
antifungal therapy. The lack of central fungal laboratories in 
Lebanon, the absence of institutional laboratory techniques for 
fungus identification, and antifungal susceptibility testing make 
most antifungal treatment based on clinical assessment.
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cOnclUsiOn
Our results showed a higher efficacy of ABLC to what has been 
previously mentioned in the literature with a comparable toxicity 
profile for the management of suspected IFD in immunocompro-
mised patients failing previous therapies. Our data were based 
on empiric or preemptive therapy due difficulty in taking tissue 
biopsies in such immunocompromised category of patients. 
Fungus identification as well as antifungal susceptibility testing 
has become an important tool for physicians in making difficult 
treatment decisions regarding management of patients with 
fungal infections, especially in the era of changing epidemiology 
and drug susceptibility patterns of both candida and mold infec-
tions (40). So, we recommend putting efforts in this issue and 
ultimately in developing an institutional antifungal stewardship 
program, which will preserve our antifungal armamentarium.
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